## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.30 indicates fundamental undervaluation. Quality metrics strong (ROE 18%). Caution: momentum weakening (-4.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($310.63)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 1)

**1. UnitedHealth exits South America with Banmedica sale**
- Source: MSN | 20251217T190442 | Bearish | Relevance: 100%
- UnitedHealth has announced its complete exit from the South American market by selling its Chilean health business, Banmedica. The sale marks a strategic shift for the U.S. healthcare giant, divesting its remaining operations in the region.

**2. UnitedHealth Group (UNH) Stock Today: Latest News, Analyst Forecasts, and What Investors Are Watching on Dec. 16, 2025**
- Source: ts2.tech | 20251216T160906 | Neutral | Relevance: 100%
- UnitedHealth Group (UNH) is under investor scrutiny on December 16, 2025, due to a dividend payment, upcoming full-year 2025 results and 2026 guidance, and significant regulatory and legal headlines affecting its Optum business. While the stock is experiencing a slight dip, investors are closely watching for clarity on medical cost trends and Medicare Advantage profitability. Analyst consensus remains broadly "Buy" with an average 12-month target of $392.24, despite ongoing volatility and regulatory pressures.

**3. UnitedHealth Group (UNH) Stock After Hours Today (Dec. 15, 2025): Key News, Analyst Forecasts, and What to Watch Before Tuesday’s Open**
- Source: ts2.tech | 20251216T000848 | Neutral | Relevance: 100%
- UnitedHealth Group (UNH) stock saw a modest dip in after-hours trading, influenced by broader industry concerns like rising medical costs and regulatory pressures, highlighted by a rival's downgrade. Investors are advised to watch key macroeconomic data releases on Tuesday morning, including jobs and retail sales reports, as these are expected to heavily impact market sentiment. UNH's next major catalyst will be its full-year 2025 results and 2026 guidance, scheduled for January 27, 2026.

**4. UnitedHealth Group (UNH) Stock After Hours Today: Key Headlines, Analyst Forecasts, and What to Watch Before the Market Opens Dec. 18, 2025**
- Source: ts2.tech | 20251218T001051 | Neutral | Relevance: 100%
- UnitedHealth Group (UNH) shares concluded Wednesday's session on a cautious note, sliding further in after-hours trading due to a major investigative report, a general risk-off sentiment in U.S. equities, and a busy macro calendar. The stock dipped modestly, with its regular session close at $331.51 and after-hours quote at $330.19 as of 18:31:35 ET. Investors are particularly focused on a Guardian investigation into UnitedHealth’s nursing home program, upcoming economic data, and analyst forecasts that view 2026 as a potential "reset year" for growth despite the current challenges.

**5. UnitedHealth Exits South America With Banmedica Sale**
- Source: Yahoo! Finance Canada | 20251217T185542 | Neutral | Relevance: 100%
- UnitedHealth Group has agreed to sell Banmedica, its final South American operation, to Brazilian private equity firm Patria Investments for $1 billion. This sale completes UnitedHealth's withdrawal from Latin America, a process that began in 2022 and has incurred an $8.3 billion loss for the company. The exit allows CEO Stephen Hemsley to refocus on core business growth, with projections for momentum to build into 2027.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 23 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Long-term trend broken: trading 7.8% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.30 suggests fair value with growth premium. Forward P/E 18.5x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $297.2B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.30 |
| Forward P/E | 18.5 |
| Current P/E | 20.1 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.2% to 0.8% (-4.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.2pp (needs >4.0% for momentum thesis). MRS_5 (-2.2%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (0.93), confirming momentum. RSI neutral at 47. OFD pattern: -DLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.82% (CS: 48) | Neutral |
| RSI_14 | 47.1 | Neutral |
| MACD Histogram | 0.93 | Bullish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 0.970x | Below |
| vs SMA200 | 0.922x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $327.99
- **Stop Loss:** $310.63 (5.3% risk)
- **Target:** $362.71 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 54
- **Position Value:** $17,711.46
- **Portfolio %:** 17.71%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*